A search for biomarkers for early detection of colorectal cancer

September 25, 2007

Researchers at the Zhejiang University, Hangzhou have discovered that mimecan and Thioredoxin Domain-Containing Protein 5 (TXNDC5) were differentially expressed in colorectal adenoma. The research article describing this work entitled "Differential Expression of Mimecan and Thioredoxin Domain-Containing Protein 5 in Colorectal Adenoma and Cancer: A Proteomic Study" will be featured in the October 2007 issue of Experimental Biology and Medicine.

Adenoma is the major precursor lesion of colorectal cancer, one of the most common cancers worldwide. The elucidation of the molecular mechanism underlying adenoma is essential for early detection, prevention and intervention of colorectal cancer.

The research team, led by Maode Lai, a professor of molecular pathology, found 27 differentially expressed proteins in colorectal adenoma using two dimensional electrophoresis (2-DE) and mass spectrometry. Western-blot analysis clearly validated 2 differentially expressed proteins, mimecan downregulation and TXNDC5 upregulation in colorectal adenomas and cancers.

"Adenoma is a very important step in the development of cancer. Discovering the biomarker of adenoma will improve the early detection and prevention of cancer," said Lai. "2-DE is an efficient traditional approach for the identification of differentially expressed proteins in cancer biology. Using this technology, we first identified 27 differentially expressed proteins in individual-matched colorectal normal, adenoma and cancer tissues."

"This study found two novel proteins which have never been found to be associated with colorectal cancer. We clearly demonstrated that absence of mimecan and up-regulation of TXNDC5 were involved in the early development of colorectal cancer," said the article's first author Yinghong Wang. "Our further work showed that mimecan can inhibit cell growth and induce cell apoptosis in colorectal cancer cells implying a candidate role as a tumor suppressor gene for the mimecan gene. These results suggested that mimecan might serve as a potential biomarker for future gene therapy."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Lai and his colleagues have performed a protein profiling proteomic study to understand the molecular mechanisms leading to colorectal cancer. It is this type of approach which can lead to the identification of biomarkers for the early detection of colorectal cancer, and targets for future gene therapy".

Society for Experimental Biology and Medicine

---

---

	American Cancer Society's Complete Guide to Colorectal Cancer by American Cancer Society (Author), Bernard Levin (Editor), Terri Ades (Editor), Katie Couric (Editor) Created by a prestigious panel of experts, this new book offers comprehensive coverage of colorectal cancer, the second most prevalent form of cancer in the world, which, with proper screening, is almost entirely preventable. It provides up-to-date, essential information about the disease, including prevention, detection, diagnosis, treatment options, complementary and alternative therapies, coping, living well with cancer, caregiving, and much more. Throughout the text real cancer survivors offer their experience dealing with this disease, from diagnosis to treatment and beyond.
	ABC of Colorectal Cancer (ABC Series) by Annie Young (Editor), Richard Hobbs (Editor), David Kerr (Editor) Colorectal cancer is a common cause of morbidity and mortality in which prevention, screening and early detection are vital. Beginning with the patient perspective and following the patient pathway, this new second edition covers epidemiology and prevention, screening programmes, decision support networks, the role of primary care, and supportive care for patients with colorectal cancer.The ABC of Colorectal Cancer provides the core knowledge on clinical genetics, diagnosis, imaging, therapy and surgery options and the latest evidence based guidelines for treating and managing colorectal cancer patients within the multidisciplinary team. Highly illustrated and accessible, it covers the full spectrum of the disease to provide the basis to make a real difference to clinical management.This...
	Be a Survivor Colorectal Cancer Treatment Guide by Vladimir Lange (Author) Dr. Lange’s comprehensive overview of cancer and treatment options offers detailed information using simple, concise language and a wide variety of color photos and drawings. Colorectal cancer patients need to know more about their disease, yet there is an overload of information. Be a Survivor gives the patient the specific, reliable and necessary information to make good decisions about their cancer and treatment options. Annually, 150,000 Americans are told they have colorectal cancer, making it one of the top three most common cancers in the United States. Diagnosed early, colorectal cancer is treatable, often curable, and vey preventable. This resource covers all aspects of colorectal cancer—from diagnosis to recovery, including a chapter for the patient's spouse.
	What Your Doctor May Not Tell You About(TM) Colorectal Cancer: New Tests, New Treatments, New Hope by Mark Bennett Pochapin (Author) - What Your Doctor May Not Tell You About Colorectal Cancer was published in Warner hardcover (0-446-53188-X) in 3/04. The book features a foreword by Katie Couric. - Dr. Pochapin made an appearance on the Today show in conjunction with the hardcover publication of this book. Previously, he had been chosen by Katie Couric to be the Medical Director of the Jay Monahan Center for Gastrointestinal Health, named in honor of Ms. Couric's late husband. - The author is an associate professor of clinical medicine at the Weill Medical College of Cornell University and Chief of Gastrointestinal Endoscopy at New York Presbyterian Hospital's Weill Cornell Medical Center. - There are approximately 100,000 new colorectal cancer cases diagnosed annually, making it the second leading cause of...
	Positive Options for Colorectal Cancer: Self-Help and Treatment by Carol Ann Larson (Author), Kathleen Ogle (Foreword) Colorectal cancer develops slowly over a period of several years, undetected, usually as polyps. It is a preventable and treatable disease if caught in time, yet most know little about how to read its symptoms. Written for the layperson, this book covers all the uncomfortable questions and answers about the disease, from prevention and warning signs, to screening and diagnosis techniques, to making decisions and developing treatment plans. Also included are positive stories about life after cancer by 12 survivors.
	COPING WITH COLORECTAL CANCER by Crystal Night Books DESCRIPTION: Coping With Colorectal Cancer – the prevention and cure of the second leading cause of cancer deaths is dedicated to helping reduce the toll this disease takes on human lives. It aims at prevention by teaching people to avoid the risk factors that lead to the disease, to save lives through leading victims to early detection, and presenting treatment options to those patients diagnosed with the disease. Colorectal cancer, also commonly called bowel cancer, is caused by uncontrolled cell growth in the colon, rectum, or appendix. Actually the majority colorectal cancers occurs due to lifestyle and increasing age, while a minority of cases are associated with underlying genetic disorders. Colorectal cancer typically starts in the lining of the bowel and...
	100 Questions & Answers About Colorectal Cancer by David Bub (Author), Susannah L. Rose (Author), W. Douglas Wong (Author) Whether You’Re A Newly Diagnosed Cancer Patient, A Survivor, Or A Friend Or Relative Of Either, This Book Offers Help. The Only Text To Provide The Doctor’S And Patient’S View, The Second Edition Is Updated With Authoritative, Practical Answers To Your Questions About Treatment Options, Post-Treatment Quality Of Life, Sources Of Support, And Much More. This Book Is An Invaluable Resource For Anyone Coping With The Physical And Emotional Turmoil Of This Frightening Disease. The Authors Consist Of Two Oncologic Surgeons And A Cancer Care Social Worker From Memorial Sloan-Kettering Cancer Center. Commentary From Actual Colon And Rectal Cancer Survivors Provides A Unique, “Insider’S” Perspective.
	Brush sampling screen preferred for colorectal ca: patient friendly.(cancer)(Gastroenterology): An article from: Internal Medicine News by Sharon Worcester (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2003. The length of the article is 597 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Brush sampling screen preferred for colorectal ca: patient friendly.(cancer)(Gastroenterology) Author: Sharon Worcester Publication: Internal Medicine News (Magazine/Journal) Date: September 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 17 Page: 45(1) Distributed by Thomson...
	Statins may reduce risk of colorectal cancer.(Across Specialties): An article from: Clinical Psychiatry News by Erik L. Goldman (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on February 1, 2005. The length of the article is 822 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Statins may reduce risk of colorectal cancer.(Across Specialties) Author: Erik L. Goldman Publication: Clinical Psychiatry News (Magazine/Journal) Date: February 1, 2005 Publisher: International Medical News Group Volume: 33 Issue: 2 Page: 75(1) Distributed by Thomson...
	High-dose aspirin long-term reduces colorectal cancer (Postgraduate Medicine) by JTE Multimedia Results reported in the Journal of the American Medical Association by Chan and colleagues (2005) suggest that optimal chemoprevention for colorectal cancer requires long-term use of aspirin doses substantially higher than those recommended for prevention of cardiovascular disease. Randomized trials have considered short-term aspirin use for prevention of recurrent colorectal adenoma. These trials have provided compelling evidence of a causal relationship between aspirin and colorectal neoplasia. However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited. Original Publication Date: November 2005